## 4 October 2016

## Ferrum Crescent Limited

("Ferrum Crescent", the "Company" or the "Group")(ASX: FCR, AIM: FCR, JSE: FCR)

## Grant of Options

Ferrum Crescent, the ASX, AIM and JSE quoted metals project developer, announces that, following receipt of shareholder approval on 29 September 2016, and further to the Company's announcement of 25 July 2016, the Company has granted 187,226,485 new unlisted options to investors who subscribed for Placing Shares on a one for one basis (the "Options") and 18,722,649 new unlisted options to Beaufort Securities Limited (the "Broker Options") as settlement of certain corporate broking services fees. The Options and Broker Options are exercisable at 0.30 pence per share on or before 29 July 2018.

Please refer to the attached Appendix 3B for further details.

For further information on the Company, please visit www.ferrumcrescent.com or contact:

## Ferrum Crescent Limited

Justin Tooth, Executive Chairman
Grant Button, Company Secretary
T: +61 894742995
UK enquiries:
Laurence Read (UK representative)
T: +447557672432
Strand Hanson Limited (Nominated Adviser)
Rory Murphy/Matthew Chandler
T: +44 (0)20 74093494
Beaufort Securities Limited (Broker)
Elliot Hance
T: +44 (0)20 73828300
Bravura Capital (Pty) Ltd (JSE Sponsor)
Doné Hattingh
T (direct): +27 114595037

## Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity
Ferrum Crescent Limited (the Company)

ABN
58097532137

We (the entity) give ASX the following information.

## Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).
$1 \quad{ }^{+}$Class of ${ }^{+}$securities issued or to be issued

Unlisted Options
(1) 187,226,485 (Placement Options)
(2) 18,722,649 (Broker Options) (together, the Unlisted Options)

Unlisted Options exercisable at 0.30 pence on or before 29 July 2018

4 Do the ${ }^{+}$securities rank equally in all respects from the ${ }^{+}$issue date with an existing +class of quoted ${ }^{+}$securities?

If the additional ${ }^{+}$securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5
Issue price or consideration

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

No - Unlisted Options*
*Shares issued on exercise of the Unlisted Options will, from the date of issue, rank equally in all respects with all existing shares on issue.

## Nil

(1) Placement Options issued to investors who subscribed for Placing Shares issued by the Company by private placement (as announced on 25 July 2016) on a one for one basis.
(2) Broker Options issued to Beaufort Securities Limited as settlement of certain corporate broking services fees owed by the Company incurred in connection with the private placement.

The issue of the Unlisted Options will not raise any funds, however, the proceeds from the exercise of the Unlisted Options will be used for the Group's general working capital requirements.

6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b-6h in relation to the ${ }^{+}$securities the subject of this Appendix 3B, and comply with section 6 i

6b The date the security holder resolution under rule 7.1 A was passed

30 November 2015

6c Number of ${ }^{+}$securities issued without security holder approval under rule 7.1

6d Number of ${ }^{+}$securities issued with security holder approval under rule 7.1A

6e Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

6 f Number of ${ }^{+}$securities issued

6 g If +securities issued under rule 7.1A, was issue price at least $75 \%$ of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

6h If +securities were issued under rule 7.1 A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6 i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1 A - complete Annexure 1 and release to ASX Market Announcements

```
Listing Rule 7.1-132,868,597
Listing Rule 7.1A - 158,255,759
```

$\qquad$

7
${ }^{+}$Issue dates
Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.
$\square$
$\square$
(1) 187,226,485 Placement Options; and (2) 18,722,649 Broker Options, issued with shareholder approval obtained at the General Meeting of the Company held on 29 September 2016.

## under an exception in rule 7.2

$\square$


8 Number and ${ }^{+}$class of all +securities quoted on ASX (including the ${ }^{+}$securities in section 2 if applicable)

| Number | ${ }^{+}$Class |
| :--- | :--- |
| $1,684,772,634$ | Ordinary shares |
|  |  |
|  |  |



10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

There is currently no dividend policy in place for the Company.

## Part 2 - Pro rata issue

11 Is security holder approval | N/A |
| :--- |
| required? |

12 Is the issue renounceable or non- N/A renounceable?

```
N/A
```

13 Ratio in which the ${ }^{+}$securities will be offered $\square$
$14{ }^{+}$Class of ${ }^{+}$securities to which the offer relates

15 +Record date to determine entitlements

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

17 Policy for deciding entitlements in relation to fractions

N/A

Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.
Cross reference: rule 7.7.
19 Closing date for receipt of N/A acceptances or renunciations
20 Names of any underwriters
N/A
N/A
$21 \begin{aligned} & \text { Amount of any underwriting fee } \mathrm{N} / \mathrm{A} \\ & \text { or commission }\end{aligned}$
22 Names of any brokers to the issue $\square$

23 Fee or commission payable to the broker to the issue

N/A


25 If the issue is contingent on security holders' approval, the date of the meeting

26 Date entitlement and acceptance form and offer documents will be sent to persons entitled
$\square$
payable to brokers who lodge acceptances or renunciations on behalf of security holders
N/A

27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
$\square$

28 Date rights trading will begin (if applicable)

N/A
-
29 Date rights trading will end (if $\mathrm{N} / \mathrm{A}$ applicable)


30 How do security holders sell their entitlements in full through a broker? $\square$
31 How do security holders sell part of their entitlements through a broker and accept for the balance?


32 How do security holders dispose of their entitlements (except by sale through a broker)? $\square$


## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities
34 Type of +securities (tick one)
(a)
 +Securities described in Part 1
(b) $\square$ All other ${ }^{+}$securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

## Entities that have ticked box 34(a)

## Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents
additional ${ }^{+}$securities, and the number and percentage of additional ${ }^{+}$securities held by those holders

If the ${ }^{+}$securities are ${ }^{+}$equity securities, a distribution schedule of the additional ${ }^{+}$securities setting out the number of holders in the categories
1-1,000 1,001-5,000
5,001-10,000
10,001-100,000
100,001 and over

37
$\square$ A copy of any trust deed for the additional ${ }^{+}$securities

## Entities that have ticked box 34(b)

Number of ${ }^{+}$securities for which ${ }^{+}$quotation is sought $\square$
${ }^{+}$Class of ${ }^{+}$securities for which quotation is sought

Do the ${ }^{+}$securities rank equally in all respects from the ${ }^{+}$issue date with an existing ${ }^{+}$class of quoted ${ }^{+}$securities?

If the additional ${ }^{+}$securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Reason for request for quotation now
Example: In the case of restricted securities, end of restriction period
(if issued upon conversion of another ${ }^{+}$security, clearly identify that other ${ }^{+}$security)

| 42 Number and ${ }^{+}$class of all ${ }^{+}$securities quoted on ASX (including the ${ }^{+}$securities in clause 38) |  | Number | ${ }^{+}$Class |
| :---: | :---: | :---: | :---: |
|  |  |  |  |

## Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the ${ }^{+}$securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any ${ }^{+}$securities to be quoted and that no-one has any right to return any ${ }^{\text {s securities to be }}$ quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the ${ }^{\text {s }}$ ecurities be quoted.
- If we are a trust, we warrant that no person has the right to return the ${ }^{+}$securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ${ }^{+}$securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ${ }^{+}$quotation of the ${ }^{+}$securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.


Date: 4 October 2016 Company secretary
Print name: Grant Button

# Appendix 3B - Annexure 1 

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

| Rule 7.1 - Issues exceeding 15\% of capital |  |
| :---: | :---: |
| Step 1: Calculate " $A$ ", the base figure from which the placement capacity is calculated |  |
| Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue | 618,787,353 |
| Add the following: <br> - Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 <br> - Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval <br> - Number of partly paid +ordinary securities that became fully paid in that 12 month period <br> Note: <br> - Include only ordinary securities here other classes of equity securities cannot be added <br> - Include here (if applicable) the securities the subject of the Appendix $3 B$ to which this form is annexed <br> - It may be useful to set out issues of securities on different dates as separate line items | $\begin{aligned} & \text { 149,681,797 (29 February 2016) } \\ & \text { 500,000,000 (12 May 2016) } \\ & \text { 4,807,692 (12 May 2016) } \\ & \text { 5,000,000 (12 May 2016) } \\ & 66,874,816 \text { (29 July 2016) } \\ & \text { 187,226,485 (29 July 2016) } \\ & \text { 44,797,543 (30 August 2016) } \\ & \text { 5,381,907 (28 September 2016) } \end{aligned}$ |
| Subtract the number of fully paid +ordinary securities cancelled during that 12 month period | 0 |
| "A" | 1,582,557,593 |

Step 2: Calculate 15\% of " $A$ "

| "B" | 0.15 <br> [Note: this value cannot be changed] |
| :--- | :--- |
| Multiply "A" by 0.15 | $237,383,638$ |

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of ${ }^{+}$equity securities issued or agreed to be issued in that 12 month period not counting those issued:

- Under an exception in rule 7.2
- Under rule 7.1A
- With security holder approval under rule 7.1 or rule 7.4
Note:
- This applies to equity securities, unless specifically excluded - not just ordinary securities
- Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed
- It may be useful to set out issues of securities on different dates as separate line items

| "C" | $104,515,041$ |
| :--- | :--- |

Step 4: Subtract " $C$ " from [" $A$ " $x$ " $B$ "] to calculate remaining placement capacity under rule 7.1

| "A" x 0.15 | $237,383,638$ |
| :--- | :--- |
| Note: number must be same as shown in <br> Step 2 |  |
| Subtract "C" <br> Note: number must be same as shown in <br> Step 3 <br> Total ["A" x 0.15] - "C" | $104,515,041$ |

## Part 2

| Rule 7.1A - Additional placement capacity for eligible entities |  |
| :--- | :--- |
| Step 1: Calculate "A", the base figure from which the placement <br> capacity is calculated |  |
| "A" <br> Note: number must be same as shown in <br> Step 1 of Part 1 <br> Step 2: Calculate 10\% of "A" <br> "D" <br> Multiply "A" by 0.10 <br> Step 3: Calculate "E", the amount of placement capacity under rule <br> 7.1A that has already been used <br> Insert number of tequity securities issued <br> or agreed to be issued in that 12 month <br> period under rule 7.1A <br> Notes: <br> This applies to equity securities - not <br> just ordinary securities <br> - Include here - if applicable - the <br> securities the subject of the Appendix <br> 3B to which this form is annexed <br> - Do not include equity securities issued <br> under rule 7.1 (they must be dealt with <br> in Part 1), or for which specific security <br> holder approval has been obtained <br> - It may be useful to set out issues of <br> securities on different dates as <br> separate line items <br> "E" |  |

[^0]| Step 4: Subtract " $E$ " from [" $A$ " $x$ " $D$ "] to calculate remaining placement capacity under rule 7.1A |  |
| :---: | :---: |
| "A" x 0.10 | 158,255,759 |
| Note: number must be same as shown in Step 2 |  |
| Subtract " E " | 0 |
| Note: number must be same as shown in Step 3 |  |
| Total ["A" x 0.10] - "E" | 158,255,759 |


[^0]:    + See chapter 19 for defined terms.

